ArticleJournal of immunology (Baltimore, Md. : 1950)2009
Analysis of the role of tripeptidyl peptidase II in MHC class I antigen presentation in vivo.
Article in Journal of immunology (Baltimore, Md. : 1950), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Beyond Sequence: Posttranslational Remodeling of Antigens in Autoimmunity.Immunological reviews · 2026Review
- Machine perception liquid biopsy identifies brain tumours via systemic immune and tumour microenvironment signature.Nature nanotechnology · 2026Article
- Proteostasis in T cell aging.Seminars in immunology · 2023Review
- Mitochondrial fission induces immunoescape in solid tumors through decreasing MHC-I surface expression.Nature communications · 2022Article
- TPP2 mutation associated with sterile brain inflammation mimicking MS.Neurology. Genetics · 2018Article
- Cytosolic Processing Governs TAP-Independent Presentation of a Critical Melanoma Antigen.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- Tripeptidyl Peptidase II Mediates Levels of Nuclear Phosphorylated ERK1 and ERK2.Molecular & cellular proteomics : MCP · 2015Article
- Article
- Review
- Sequence-specific alterations of epitope production by HIV protease inhibitors.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- The VHSE-based prediction of proteasomal cleavage sites.PloS one · 2013Article
- Tripeptidyl peptidase II regulates sperm function by modulating intracellular Ca(2+) stores via the ryanodine receptor.PloS one · 2013Article
- Towards a systems understanding of MHC class I and MHC class II antigen presentation.Nature reviews. Immunology · 2011Review
- Variable HIV peptide stability in human cytosol is critical to epitope presentation and immune escape.The Journal of clinical investigation · 2011Article
- Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes.Cellular and molecular life sciences : CMLS · 2011Review
- Post-proteasomal and proteasome-independent generation of MHC class I ligands.Cellular and molecular life sciences : CMLS · 2011Review
- Tripeptidyl Peptidase II Is Required for c-MYC-Induced Centriole Overduplication and a Novel Therapeutic Target in c-MYC-Associated Neoplasms.Genes & cancer · 2010Article
- Hybrid molecular structure of the giant protease tripeptidyl peptidase II.Nature structural & molecular biology · 2010Article
- Production of an antigenic peptide by insulin-degrading enzyme.Nature immunology · 2010Article
- The Enigma of Tripeptidyl-Peptidase II: Dual Roles in Housekeeping and Stress.Journal of oncology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Previous experiments using enzyme inhibitors and RNA interference in cell lysates and cultured cells have suggested that tripeptidyl peptidase II (TPPII) plays a role in creating and destroying MHC class I-presented peptides. However, its precise contribution to these processes has been controversial. To elucidate the importance of TPPII in MHC class I Ag presentation, we analyzed TPPII-deficient gene-trapped mice and cell lines from these animals. In these mice, the expression level of TPPII was reduced by >90% compared with wild-type mice. Thymocytes from TPPII gene-trapped mice displayed more MHC class I on the cell surface, suggesting that TPPII normally limits Ag presentation by destroying peptides overall. TPPII gene-trapped mice responded as well as did wild-type mice to four epitopes from lymphocytic choriomeningitis virus. The processing and presentation of peptide precursors with long N-terminal extensions in TPPII gene-trapped embryonic fibroblasts was modestly reduced, but in vivo immunization with recombinant lentiviral or vaccinia virus vectors revealed that such peptide precursors induced an equivalent CD8 T cell response in wild-type and TPPII-deficient mice. These data indicate that while TPPII contributes to the trimming of peptides with very long N-terminal extensions, TPPII is not essential for generating most MHC class I-presented peptides or for stimulating CTL responses to several Ags in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.